Skip to main content

Table 3 Medication during hospitalization and hospitalization days

From: Clinical trends among patients with asthma hospitalized for COVID-19 based on data from a nationwide database: an observational study

Variable

Category

Jan, 2020 – Jun, 2021 (n = 46,336)

Jul, 2021 – Dec, 2022 (n = 26,246)

Non-asthma, COPD

Asthma

COPD

Asthma+COPD

Non-asthma, COPD

Asthma

COPD

Asthma+COPD

42,819

2302

1087

128

23,905

1429

820

92

Treatment (%)

Yes

21,913 (51.2)

1295 (56.3)

775 (71.3)

92 (71.9)

15,393 (64.4)

961 (67.2)

644 (78.5)

70 (76.1)

Remdesivir (%)

Yes

7387 (17.3)

455 (19.8)

329 (30.3)

37 (28.9)

9292 (38.9)

533 (37.3)

402 (49.0)

42 (45.7)

Tocilizumab (%)

Yes

1272 (3.0)

70 (3.0)

53 (4.9)

4 (3.1)

634 (2.7)

40 (2.8)

21 (2.6)

2 (2.2)

Corticosteroid (%)

Yes

14,318 (33.4)

893 (38.8)

630 (58.0)

74 (57.8)

6817 (28.5)

446 (31.2)

294 (35.9)

29 (31.5)

mPSL1000mg/day

 

1076 (2.5)

56 (2.4)

55 (5.1)

10 (7.8)

547 (2.3)

18 (1.3)

28 (3.4)

547 (2.3)

mPSL1mg/kg/day

 

1263 (2.9)

67 (2.9)

51 (4.7)

10 (7.8)

134 (0.6)

6 (0.4)

6 (0.7)

134 (0.6)

DEX6mg/day

     

5532 (23.1)

350 (24.5)

232 (28.3)

20 (21.7)

Hospitalization days (mean SD)

 

15.05 (19.40)

14.17 (16.47)

21.20 (23.34)

23.54 (37.45)

15.50 (28.00)

12.58 (18.07)

20.88 (28.65)

17.72 (14.37)

  1. COPD chronic obstructive pulmonary disease, mPSL methylprednisolone, DEX dexamethasone